The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
 
John C. Byrd
Stock and Other Ownership Interests - Eilean Pharma; Kurome Therapeutics; Vincerx Pharma
Consulting or Advisory Role - Eilean; Kartos Therapeutics; Kurome Therapeutics; Newave Pharmaceutical; Orange Grove Bio; Orbimed; Vincerx Pharma
Research Funding - Eilean Pharma (Inst); Newave Pharmaceutical (Inst); Orbimed
Patents, Royalties, Other Intellectual Property - OSU Patents
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Novartis; Pharmacyclics; TG Therapeutics
 
Pierluigi Porcu
Honoraria - Daiichi Sankyo/UCB Japan; Innate Pharma; Kiowa; Viracta Therapeutics
Consulting or Advisory Role - DAAN Biotherapeutics; Innate Pharma; Kiowa; Viracta Therapeutics
Research Funding - Ono Pharmaceutical (Inst)
 
Thomas Sundermeier
Employment - ONO PHARMA USA, INC.
 
Takashi Nakada
Employment - ONO PHARMA USA, INC.
 
Takeyuki Iwata
Employment - ONO PHARMA USA, INC.
Stock and Other Ownership Interests - Astellas Pharma; ONO PHARMACEUTICAL CO., LTD,; Takeda
 
Sergio Prados
Employment - ONO PHARMA, USA, INC.
 
Leo I. Gordon
Stock and Other Ownership Interests - Zylem
Consulting or Advisory Role - Bristol Meyers Squibb; Kite, a Gilead company; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - Zylem